Alvotech (ALVO)

• Market cap: $1.9B
• 1 day: -1.12%
• 5 days: 6.4%
• 1 month: 38.54%
• 3 months: 42.25%
• 6 months: 36.76%
• Year to date: 6.4%
• 1 year: -33.83%
• 5 years: -52.46%
• 10 years: -52.46%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

Employees: 1,460